Abstract
In diabetic disease, blood glucose, HbA1c and insulin levels qualify as biomarkers reflecting endocrine pancreas function, but their shortfall in being truly useful predictors or surrogate endpoints of “abnormal processes or disease“ lies in that alteration in their levels are dependent on a variety comorbidities and occur too late in the disease process to be useful sentinels. Non invasive imaging of molecular targets within the beta cell carry the promise of revealing quantitative information about β-cell mass that can, at least theoretically, be used to monitor, in real-time, the natural history of T1DM progression, assess novel therapies designed to drive the proliferation and differentiation of endogenous beta cell progenitors, appraise methods of preserving mature beta cell mass as well as to track the function and viability of transplanted cells and tissues. In this article, we review and deconstruct available information regarding the methodology of making non invasive measurements of VMAT2 in the pancreas and the validity of these measurements to estimate beta cell mass in vivo.
Keywords: VMAT2, PET, diabetes, beta cell mass, DTBZ
Current Pharmaceutical Design
Title: In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Volume: 16 Issue: 14
Author(s): Rajakrishnan Veluthakal and Paul Harris
Affiliation:
Keywords: VMAT2, PET, diabetes, beta cell mass, DTBZ
Abstract: In diabetic disease, blood glucose, HbA1c and insulin levels qualify as biomarkers reflecting endocrine pancreas function, but their shortfall in being truly useful predictors or surrogate endpoints of “abnormal processes or disease“ lies in that alteration in their levels are dependent on a variety comorbidities and occur too late in the disease process to be useful sentinels. Non invasive imaging of molecular targets within the beta cell carry the promise of revealing quantitative information about β-cell mass that can, at least theoretically, be used to monitor, in real-time, the natural history of T1DM progression, assess novel therapies designed to drive the proliferation and differentiation of endogenous beta cell progenitors, appraise methods of preserving mature beta cell mass as well as to track the function and viability of transplanted cells and tissues. In this article, we review and deconstruct available information regarding the methodology of making non invasive measurements of VMAT2 in the pancreas and the validity of these measurements to estimate beta cell mass in vivo.
Export Options
About this article
Cite this article as:
Veluthakal Rajakrishnan and Harris Paul, In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives, Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164180
DOI https://dx.doi.org/10.2174/138161210791164180 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Drug Targets in the Management of Type 2 Diabetes
Current Drug Targets The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Early Cerebral Infarction Following Aneurysmal Subarachnoid Hemorrhage: Frequency, Risk Factors, Patterns, and Prognosis
Current Neurovascular Research Emerging Role of JNK in Insulin Resistance
Current Diabetes Reviews Definitions of Metabolic Syndrome: Where are We Now?
Current Vascular Pharmacology Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Breastfeeding and Diabetes
Current Diabetes Reviews Isolated Anosmia as a Presentation of COVID-19: An Experience in a Referral Hospital
Infectious Disorders - Drug Targets Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Alterations in the Expression of Amyloid Precursor Protein Cleaving Enzymes mRNA in Alzheimer Peripheral Blood
Current Alzheimer Research Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Increased Paternal Age and Child Health and Development
Current Pediatric Reviews An Insight to the Toxic Effect of Sulfamerazine on Porcine Pancreatic Amylase and Lactate Dehydrogenase Activity: An In Vitro Study
Current Chemical Biology Oral Chemotherapy in Elderly Women with Metastatic Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry TP Receptor as a Therapeutic Target in Atherosclerosis and Related Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Improved Insulin Resistance through Cajanus cajan extract in Gestational Diabetes Mellitus of Wistar Rat
Current Women`s Health Reviews Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Long-Acting Antipsychotic Medications
Current Drug Targets